To this effect, a mixture of PBMC and HER2+ tumor cells was first exposed to margetuximab in the presence or absence of tebotelimab, followed by ADCC against margetuximab-opsonized HER2+ tumor cells. This evidence concerns the gene ERBB2 and neoplasm.